Benitec Biopharma to Present at The 14th Annual BIO Investor Forum

SYDNEY, Oct. 14, 2015 /PRNewswire/ -- Benitec Biopharma (ASX: BLT; NASDAQ: BNTC), a clinical-stage biotechnology company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), today announced that it will present at The 14th Annual BIO Investor Forum to be held October 20-21, 2015 at the Parc 55 San Francisco.

David Suhy, Ph.D., Chief Scientific Officer of Benitec, will provide an overview of the company's business and clinical-stage development pipeline, including its lead product, TT-034, during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Dr. Suhy's presentation will be webcast live and made available as an archive on Benitec Biopharma's website, www.benitec.com.

About Benitec Biopharma Limited

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC) is a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward, CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa. For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

Contacts:

SOURCE Benitec Biopharma

Related Links

http://www.benitec.com